These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29623443)

  • 21. Reinforcement of an antimicrobial stewardship task force aims at a better use of antibiotics of last resort: the COLITIFOS study.
    Davido B; Bouchand F; Dinh A; Perronne C; Villart M; Senard O; Salomon J
    Int J Antimicrob Agents; 2017 Aug; 50(2):142-147. PubMed ID: 28694232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
    Evans ME; Feola DJ; Rapp RP
    Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New information about the polymyxin/colistin class of antibiotics.
    Molina J; Cordero E; Pachón J
    Expert Opin Pharmacother; 2009 Dec; 10(17):2811-28. PubMed ID: 19929704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.
    Najmeddin F; Ahmadi A; Mahmoudi L; Sadeghi K; Khalili H; Ahmadvand A; Najafi A; Mojtahedzadeh M
    Acta Med Iran; 2014; 52(9):703-9. PubMed ID: 25325208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
    Mueller EW; Boucher BA
    Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revival of old antibiotics: needs, the state of evidence and expectations.
    Zayyad H; Eliakim-Raz N; Leibovici L; Paul M
    Int J Antimicrob Agents; 2017 May; 49(5):536-541. PubMed ID: 28162982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.
    D'Avolio A; Pensi D; Baietto L; Pacini G; Di Perri G; De Rosa FG
    Drugs; 2016 Aug; 76(12):1161-74. PubMed ID: 27412121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
    Kassamali Z; Jain R; Danziger LH
    Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.
    Bulitta JB; Landersdorfer CB; Forrest A; Brown SV; Neely MN; Tsuji BT; Louie A
    Curr Pharm Biotechnol; 2011 Dec; 12(12):2044-61. PubMed ID: 21554212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
    Zavascki AP; Klee BO; Bulitta JB
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing use of aminoglycosides in the critically ill.
    Rea RS; Capitano B
    Semin Respir Crit Care Med; 2007 Dec; 28(6):596-603. PubMed ID: 18095223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Multidrug-Resistant Gram-negative Superbugs Threat Require Intelligent Use of the Last Weapon.
    Deris ZZ
    Malays J Med Sci; 2015 Sep; 22(5):1-6. PubMed ID: 28239263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous polymyxins: Revival with puzzle.
    Yu Y; Fei A; Wu Z; Gao C; Pan S
    Biosci Trends; 2017; 11(4):370-382. PubMed ID: 28904326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia.
    Scaglione F
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S33-9. PubMed ID: 21129926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.
    Lakota EA; Landersdorfer CB; Nation RL; Li J; Kaye KS; Rao GG; Forrest A
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens.
    Scaglione F; Paraboni L
    Int J Antimicrob Agents; 2008 Oct; 32(4):294-301. PubMed ID: 18621508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients.
    Mohr JF; Wanger A; Rex JH
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):125-30. PubMed ID: 14972382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.